Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).

[1]  K. Clément,et al.  Macrophage activation marker soluble CD163 and non‐alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery , 2015, Journal of gastroenterology and hepatology.

[2]  R. Moreau,et al.  The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. , 2015, Journal of hepatology.

[3]  H. Fukui.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. , 2015, World journal of hepatology.

[4]  H. Møller,et al.  Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival , 2015, Infectious diseases.

[5]  R. Jalan,et al.  Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. , 2015, Journal of hepatology.

[6]  B. Bibby,et al.  Reply: To PMID 24623375. , 2015, Hepatology.

[7]  R. Moreau,et al.  Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. , 2014, Journal of hepatology.

[8]  H. Grønbæk,et al.  Non‐alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[9]  A. Boonstra,et al.  The role of Kupffer cells in hepatitis B and hepatitis C virus infections. , 2014, Journal of hepatology.

[10]  S. Hamilton-Dutoit,et al.  Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study , 2014, The American Journal of Gastroenterology.

[11]  B. Bibby,et al.  Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C , 2014, Hepatology.

[12]  D. Brenner,et al.  Interactions between the intestinal microbiome and liver diseases. , 2014, Gastroenterology.

[13]  H. Møller,et al.  Monocyte Expression and Soluble Levels of the Haemoglobin Receptor (CD163/sCD163) and the Mannose Receptor (MR/sMR) in Septic and Critically Ill Non-Septic ICU Patients , 2014, PloS one.

[14]  H. Møller,et al.  A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness , 2013, Clinical chemistry and laboratory medicine.

[15]  J. Trojan,et al.  Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. , 2013, Journal of hepatology.

[16]  R. Butterworth.  The liver–brain axis in liver failure: neuroinflammation and encephalopathy , 2013, Nature Reviews Gastroenterology &Hepatology.

[17]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[18]  R. Moreau,et al.  Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. , 2013, Journal of hepatology.

[19]  H. Møller,et al.  Hepatic macrophage activation predicts clinical decompensation in chronic liver disease , 2013, Gut.

[20]  B. Kronenberger,et al.  Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis , 2013 .

[21]  H. Møller,et al.  Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[22]  B. Sharma,et al.  Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  L. Martínez-Pomares.  The mannose receptor , 2012, Journal of leukocyte biology.

[24]  P. Kubes,et al.  Sterile inflammation in the liver. , 2012, Gastroenterology.

[25]  H. Møller,et al.  Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis , 2012, Alimentary pharmacology & therapeutics.

[26]  B. Sharma,et al.  27 SERUM ENDOTOXINS AND INFLAMMATORY MEDIATORS IN PATIENTS WITH CIRRHOSIS AND HEPATIC ENCEPHALOPATHY , 2012 .

[27]  C. Steib.  Kupffer cell activation and portal hypertension , 2011, Gut.

[28]  S. Moestrup,et al.  Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS , 2011, Gut.

[29]  S. Moestrup,et al.  Tumor necrosis factor -converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163 , 2010 .

[30]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[31]  G. Baffy.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view. , 2009, Journal of hepatology.

[32]  William M. Lee,et al.  Soluble CD163 from activated macrophages predicts mortality in acute liver failure. , 2007, Journal of hepatology.

[33]  S. Moestrup,et al.  Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163* , 2006, Critical care medicine.

[34]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[35]  R. Groszmann,et al.  Bacterial translocation up‐regulates GTP‐cyclohydrolase I in mesenteric vasculature of cirrhotic rats , 2003, Hepatology.

[36]  J. Aparicio,et al.  Intestinal permeability is increased in patients with advanced cirrhosis. , 2003, Hepato-gastroenterology.

[37]  S. Moestrup,et al.  Characterization of an enzyme-linked immunosorbent assay for soluble CD163 , 2002, Scandinavian journal of clinical and laboratory investigation.

[38]  P. H. Petersen,et al.  Soluble CD163: a marker molecule for monocyte/macrophage activity in disease , 2002, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[39]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[40]  K. Hoppo,et al.  Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. , 2000, Alcoholism, clinical and experimental research.

[41]  F. Koning,et al.  Human dendritic cells shed a functional, soluble form of the mannose receptor. , 1999, International immunology.

[42]  R. Groszmann,et al.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. , 1999, The Journal of clinical investigation.

[43]  S. Gordon,et al.  A Functional Soluble Form of the Murine Mannose Receptor Is Produced by Macrophages in Vitro and Is Present in Mouse Serum* , 1998, The Journal of Biological Chemistry.

[44]  S. D. Lee,et al.  Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. , 1996, Scandinavian journal of gastroenterology.

[45]  E. Dupont,et al.  Tumor necrosis factor α and interleukin 6 plasma levels in infected cirrhotic patients , 1993 .

[46]  E. Dupont,et al.  Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. , 1993, Gastroenterology.